Abstract

FORMULATION DEVELOPMENT AND EVALUATION OF BRISOPROLOL FUMERATE TRANSDERMAL DRUG DELIVERY SYSTEM

Swati Rawat* and Ganesh Dewan

Abstract

Transdermal drug delivery system is a new era of pharmaceutical dosage forms along with various features to provide successful drug delivery. Transdermal drug delivery system establishes itself as an integral part of novel drug delivery system. In the present study, an attempt was made to formulation and evaluation transdermal patches of Brisoprolol Fumerate in order to overcome first pass metabolism in GIT, drug deactivation by lever and better patient complaints and to reduce adverse effect and frequency of administration. Each of the proposed transdermal patches is composed of using different polymers, anticipating thwacking drug permeation and drug release. Controlled released transdermal preparation of Brisoprolol Fumerate prepared to give sustained effect as compared to conventional multiple oral dose. A 23 factorial design was applied for preparing Bisoprolol Fumarate transdermal patch and to study the effect of independent variables i.e. HPMC K4M and carbapol 934 on various responses like In vitro drug release, % cumulative drug release moisture content, moisture uptake, tensile strength and water vapour transmission rate. The patches were transparent, smooth and flexible. The results of weight variation, thickness, moisture content, moisture uptake, folding endurance, tensile strength, drug content. The formulation F1 to F6 shows uniform weight ranging from 153.18mg to 248.50mg and thickness of F1 to F6 are ranging from 0.033 to 0.044mm. All the formulations (F1 to F6) exhibited fairly uniform drug content ranging from 91.06 to 98.05 % respectively. The moisture content was found to be in the range of 1.9 to 4.8% and moisture uptake was found to be in the range of 2.9 to 5.2%. Folding Endurance of the developed formulations F1 to F6 varied from 224 to 283. Maximum was noted for formulation F6. Batch F1 showed highest drug release (98.36%) and the lowest release was from batch F3 (93.54%). After 1month stability there is no change in prepared patch. A transdermal patch is defined as medicated adhesive patch which is placed above the skin to deliver a specific dose of medication through the skin with a predetermined rate of release to reach into the blood stream.

Keywords: Brisoprolol Fumerate, Transdermal Drug Delivery System, Carbapol 934, Folding Endurance, Tensile Strength.